Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.

Aldehyde Dehydrogenase 1 Family / metabolism Animals Brain Neoplasms / drug therapy Cell Line, Tumor Cell Proliferation / drug effects Dasatinib / pharmacology Drug Resistance, Neoplasm / drug effects ErbB Receptors / antagonists & inhibitors Erlotinib Hydrochloride / pharmacology Glioblastoma / drug therapy Humans Mice Oxidative Stress / drug effects Protein Kinase Inhibitors / pharmacology Retinal Dehydrogenase / metabolism Xenograft Model Antitumor Assays / methods

Journal

Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535

Informations de publication

Date de publication:
09 2019
Historique:
received: 01 12 2018
revised: 10 05 2019
accepted: 28 06 2019
pubmed: 5 7 2019
medline: 18 6 2020
entrez: 5 7 2019
Statut: ppublish

Résumé

Amplification of the epidermal growth factor receptor gene (

Identifiants

DOI: 10.1158/1535-7163.MCT-18-1330 PMID: 31270152 PMC: PMC6726545
pubmed: 31270152
pii: 1535-7163.MCT-18-1330
doi: 10.1158/1535-7163.MCT-18-1330
pmc: PMC6726545
mid: NIHMS1533709
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Erlotinib Hydrochloride DA87705X9K
Aldehyde Dehydrogenase 1 Family EC 1.2.1
ALDH1A1 protein, human EC 1.2.1.36
Retinal Dehydrogenase EC 1.2.1.36
EGFR protein, human EC 2.7.10.1
ErbB Receptors EC 2.7.10.1
Dasatinib RBZ1571X5H

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1565-1576

Subventions

Organisme : NCI NIH HHS
ID : U01 CA168878
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA082103
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA179071
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA097257
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA221747
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA229345
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS081117
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA211015
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Cancer Cell. 2011 Dec 13;20(6):810-7
pubmed: 22137795
Oncol Rep. 2009 Feb;21(2):483-9
pubmed: 19148526
Oncogene. 2012 Jun 21;31(25):3039-50
pubmed: 22020333
Cell Cycle. 2011 May 1;10(9):1378-84
pubmed: 21552008
Cell Physiol Biochem. 2008;22(5-6):757-68
pubmed: 19088457
Cancer Res. 2014 Jul 1;74(13):3579-90
pubmed: 24812274
Proc Natl Acad Sci U S A. 2012 Aug 28;109(35):14164-9
pubmed: 22891331
Oncotarget. 2016 Nov 29;7(48):79101-79116
pubmed: 27738329
Cancer Discov. 2013 May;3(5):534-47
pubmed: 23533263
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13
pubmed: 1584765
Am J Cancer Res. 2015 Mar 15;5(4):1471-83
pubmed: 26101711
PLoS One. 2011;6(6):e21428
pubmed: 21731744
Chem Biol Interact. 2011 May 30;191(1-3):278-87
pubmed: 21256123
Oncotarget. 2016 Dec 27;7(52):86313-86325
pubmed: 27861144
Cell Cycle. 2013 Nov 1;12(21):3390-404
pubmed: 24047698
Toxicol Pathol. 1984;12(3):235-9
pubmed: 6515277
Cancer Res. 2010 Oct 15;70(20):8117-26
pubmed: 20876798
Cancer Discov. 2012 May;2(5):450-7
pubmed: 22588882
Int J Cancer. 1998 Feb 9;75(4):578-83
pubmed: 9466659
Cancer Cell. 2002 Apr;1(3):269-77
pubmed: 12086863
Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71
pubmed: 16609043
Nat Cell Biol. 2014 May;16(5):457-68
pubmed: 24747441
FEBS Lett. 1999 Jun 25;453(3):278-82
pubmed: 10405160
Cell Stem Cell. 2007 Nov;1(5):555-67
pubmed: 18371393
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9
pubmed: 1557402
Oncotarget. 2012 Oct;3(10):1124-36
pubmed: 23165409
Science. 2014 Jan 3;343(6166):72-6
pubmed: 24310612
Nat Rev Cancer. 2015 May;15(5):302-10
pubmed: 25855404
J Biol Chem. 2007 Aug 31;282(35):25668-76
pubmed: 17567582
Br J Cancer. 2013 Oct 1;109(7):1876-85
pubmed: 24008666
Cancer Res. 2011 Jun 1;71(11):3932-40
pubmed: 21482679
Brain Pathol. 2012 Nov;22(6):788-97
pubmed: 22417385
Neuro Oncol. 2012 Dec;14(12):1452-64
pubmed: 23132408
ChemMedChem. 2012 Apr;7(4):650-62
pubmed: 22354538
J Clin Invest. 2012 Mar;122(3):911-22
pubmed: 22293178
Cell. 2013 Oct 10;155(2):462-77
pubmed: 24120142
Clin Cancer Res. 2009 Jun 15;15(12):4234-41
pubmed: 19509181
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
Mol Cell Neurosci. 2003 Dec;24(4):1116-30
pubmed: 14697673
Mol Cancer Ther. 2011 Jun;10(6):1102-12
pubmed: 21471286
Methods Mol Biol. 2015;1229:507-16
pubmed: 25325976
Cell Metab. 2013 Jun 4;17(6):1000-8
pubmed: 23707073
Nature. 2008 Oct 23;455(7216):1061-8
pubmed: 18772890
J Clin Oncol. 2008 Dec 1;26(34):5603-9
pubmed: 18955445
Clin Cancer Res. 2010 Jan 1;16(1):45-55
pubmed: 20028757
Neuro Oncol. 2010 Oct;12(10):1024-33
pubmed: 20627895
J Clin Oncol. 2009 Mar 10;27(8):1268-74
pubmed: 19204207
Cancer Discov. 2011 Oct;1(5):442-56
pubmed: 22059152
N Engl J Med. 2005 Nov 10;353(19):2012-24
pubmed: 16282176
Sci Signal. 2009 Dec 15;2(101):ra82
pubmed: 20009104

Auteurs

Andrew McKinney (A)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Olle R Lindberg (OR)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
ORCID: 0000-0001-5646-2501

Jane R Engler (JR)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Katharine Y Chen (KY)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Anupam Kumar (A)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Henry Gong (H)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Kan V Lu (KV)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Erin F Simonds (EF)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Department of Neurology, University of California, San Francisco, San Francisco, California.
ORCID: 0000-0002-3497-4861

Timothy F Cloughesy (TF)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

Linda M Liau (LM)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Department of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
ORCID: 0000-0002-4053-0052

Michael Prados (M)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Andrew W Bollen (AW)

Department of Pathology, Division of Neuropathology, University of California, San Francisco, San Francisco, California.

Mitchel S Berger (MS)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.

Joseph T C Shieh (JTC)

Division of Medical Genetics, Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, California.
Institute for Human Genetics, University of California, San Francisco, San Francisco, California.

C David James (CD)

Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Theodore P Nicolaides (TP)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, California.

William H Yong (WH)

Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

Albert Lai (A)

UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

Monika E Hegi (ME)

Neuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
ORCID: 0000-0003-0855-6495

William A Weiss (WA)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Department of Neurology, University of California, San Francisco, San Francisco, California.
Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, California.

Joanna J Phillips (JJ)

Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California. Joanna.phillips@ucsf.edu.
Department of Pathology, Division of Neuropathology, University of California, San Francisco, San Francisco, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Oxidoreductases › Oxidoreductases acting on aldehyde or oxo group donors › Aldehyde oxidoreductases › Aldehyde dehydrogenase › Aldehyde dehydrogenase 1 › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Eucaryotes › Animaux › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Dasatinib › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur facteur croissance › Récepteurs ErbB › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Quinazolines › Chlorhydrate d'erlotinib › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroépitheliales › Gliome › Astrocytome › Glioblastome › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Phénomènes physiologiques › Stress physiologique › Stress oxydatif › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Métalloprotéines › Protéines de liaison au fer › Protéines à fer non hème › Retinal dehydrogenase › Mechanisms of Resistance to EGFR Inhibition...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Tests d'activité antitumorale sur modèle de xénogreffe › Mechanisms of Resistance to EGFR Inhibition...